HB 870 requires Louisiana health insurance issuers to immediately place cheaper generic drugs and biosimilars on more favorable formulary tiers (with lower out-of-pocket costs) when their wholesale acquisition cost is lower than the brand-name reference drug or product. Specifically, if a generic drug costs less than its brand-name equivalent at launch, insurers must cover it with better cost-sharing and cannot impose prior authorization, step therapy, or pharmacy restrictions that make it harder to access than the brand. The same rules apply to biosimilars that are cheaper than their reference biological products. This directly affects health insurance plans and enrollees seeking coverage for these cost-effective alternatives. The bill aims to reduce patient costs by mandating insurer action when cheaper, equivalent options become available.
HB 1199 mandates that health insurance plans cover genetic testing and treatments for SCN2A-associated medical conditions without imposing cost-sharing fees on members who are covered under their policy. The bill requires insurers to include these specific services in their coverage without charging patients a portion of the cost. This legislation directly affects individuals with SCN2A-related conditions and the health insurance providers who must adjust their benefit structures accordingly.
HB 1160 amends the laws governing rural physician licenses by updating specific terminology and clarifying the requirements for obtaining such licenses. The bill modifies the definition of a medical degree and adds language to ensure that licensing determinations are both approved and adopted through established administrative processes. It also changes the conditions under which a physician can be licensed, requiring them to meet a specific set of criteria rather than a single provision. These changes directly affect doctors practicing in rural areas and the state agencies responsible for issuing their medical licenses.
This bill, titled the Louisiana Clinical Trial Competitiveness and Patient Access Act, aims to support economic development by establishing a framework for clinical trials within the state. It directly affects healthcare providers, pharmaceutical companies, and patients by creating new provisions to enhance the competitiveness of clinical research in Louisiana. The legislation includes specific amendments that clarify the law does not override federal restrictions and expands the scope of protected protocols to include nonpublic ones. By adding these details, the bill seeks to provide clearer guidelines for conducting clinical trials while ensuring compliance with existing federal regulations.
This bill amends Louisiana law to require the Medicaid program to cover continuous glucose monitors for pregnant women with diabetes who use insulin more than twice daily or have experienced severe low blood sugar. The change specifically includes gestational diabetes, ensuring that eligible expectant mothers receive access to these monitoring devices as part of their treatment plan. By updating the state's Medicaid statutes, the legislation directly affects pregnant enrollees and the healthcare providers who administer their care.
This bill, known as the Nursing Home Choice Act, requires Louisiana to provide counseling and alternative options to residents and families of nursing homes that receive the lowest one-star quality rating from the Centers for Medicare and Medicaid Services. When a facility is rated one star, staff must offer immediate access to community-based services or transfer residents to a higher-rated nursing home, and potential residents must be notified before placement to explore alternatives. The law also mandates that one-star facilities submit a remediation plan with specific improvement targets within 30 days, provide quarterly progress reports, and face additional monitoring and potential sanctions if they fail to improve their rating within two years. These requirements apply to all nursing homes with a one-star rating on October 1, 2026, and remain in effect until the facility achieves a rating of two stars or higher.
This bill establishes the Louisiana Medical Debt Protection Act to limit how medical creditors and debt collectors can pursue unpaid medical bills for medically necessary care. It directly affects consumers who owe money for healthcare services, including prescription drugs and transportation to medical appointments. The law caps interest on such debt at two percent per annum, prohibits wage garnishment and liens on primary homes or vehicles unless income exceeds four times the federal poverty level, and requires contracts with debt collectors to include specific restrictions. Violations can result in civil penalties, public complaints filed with the attorney general, and private lawsuits allowing recovery of damages and attorney fees.
This bill requires Louisiana Medicaid to cover FDA-approved weight loss medications for eligible adults over eighteen. To qualify, patients must have a BMI of 30 or higher with at least one related health condition like diabetes or hypertension, or a BMI of 35 or higher without additional conditions. Coverage will require prior authorization limited to verifying these eligibility criteria, with initial approval for six months and continued coverage depending on documented clinical improvement. The bill also prohibits step therapy requirements for these medications and mandates that the Department of Health implement the coverage while maintaining fiscal sustainability.
This bill requires healthcare facilities in Louisiana to provide specific behavioral health services to patients admitted under emergency certificates. Upon admission, facilities must conduct a behavioral health evaluation within 72 hours and contact the patient's primary healthcare provider to review treatment history. At discharge, staff must notify healthcare professionals about the patient's release, provide a medical summary to follow-up providers, distribute educational materials about warning signs and privacy rights, and ensure patients receive at least a 14-day medication supply. The law also mandates that the Louisiana Department of Health create and publish these educational documents for patients and their families.
This bill requires insurance contracts in Louisiana to include a minimum prescriptive period of 24 months for first-party claims and one year for other claims, preventing insurers from limiting the time policyholders have to file lawsuits. It also clarifies that making a payment under an insurance contract does not reset or extend the deadline for filing a claim. The law applies to insurance policies covering residents or property located in Louisiana, including health and accident policies for state residents.
